Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea Source: Eur Respir J, 51 (3) 1702467; 10.1183/13993003.02467-2017 Year: 2018
The treatment outcomes of isoniazid resistant tuberculosis: Multicenter and retrospective study in South Korea Source: Annual Congress 2010 - Emerging drug resistance in tuberculosis Year: 2010
Bedaquiline in the treatment of multidrug-resistant tuberculosis: a subanalysis in Korean population Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil Source: Eur Respir J , 49 (3) 1602445; DOI: 10.1183/13993003.02445-2016 Year: 2017
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa Source: Eur Respir J, 51 (6) 1800017; 10.1183/13993003.00017-2018 Year: 2018
The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017 Year: 2017
Bedaquiline containing regimens for the treatment of multi- and extensively drug-resistant tuberculosis at the programmatic level in Belarus. Prospective cohort study. Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019
A retrospective analysis of quinolone prescriptions for tuberculosis in two North Birmingham hospitals Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey Source: Eur Respir J, 51 (3) 1702571; 10.1183/13993003.02571-2017 Year: 2018
Metformin use and post-exposure incident tuberculosis: a nationwide tuberculosis-contact cohort study in Taiwan Source: ERJ Open Res, 6 (3) 00050-2020; 10.1183/23120541.00050-2020 Year: 2020
Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia Source: Eur Respir J, 51 (3) 1702550; 10.1183/13993003.02550-2017 Year: 2018
Multidrug-resistant tuberculosis in children in northwest Russia: an observational cohort study Source: Eur Respir J 2016; 48: 1496-1499 Year: 2016
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country Source: Eur Respir J, 57 (6) 2002544; 10.1183/13993003.02544-2020 Year: 2021
Treatment outcomes for multidrug-resistant tuberculosis (MDR-TB) patients in Africa Source: Annual Congress 2011 - Multidrug-resistant tuberculosis Year: 2011
Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk Source: Eur Respir J 2012; 39: 1425-1431 Year: 2012
Prospective study of mycobacterium tuberculosis drug resistance in Tunisia Source: Eur Respir J 2004; 24: Suppl. 48, 658s Year: 2004
Second-line tuberculosis drug resistance study from a referal center of Turkey Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis II Year: 2008
Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China Source: Eur Respir J , 49 (3) 1601558; DOI: 10.1183/13993003.01558-2016 Year: 2017
Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and Russia Source: Eur Respir J 2012; 40: 133-142 Year: 2012